The following post is one of a series of posts appearing Monday through Friday on The Cancer Blog. This feature -- Today, I am grateful -- allows me to share with readers my appreciation for all the treasures in my life, both big and small. In my post-cancer world, I find It healing for my soul to be mindful of the good in my life. It is my pleasure to share my gratitude with you.

The night before my lumpectomy, way back in December 2005, I was consumed with fear, worry, and panic. Since I'd found it, the lump in my left breast had been sitting untouched for nearly two weeks. I imagined the mass spreading with each day and believed I could detect its growth each time I felt for it. A doctor told me if it was growing like I thought it was, my tiny pea-sized tumor would be the size of an apple within days.

My fears were unfounded and irrational. I know that now. But during the moments of uncertainty that filled my days between diagnosis and prognosis, I had no direction. I had only my wandering mind for company. The waiting really is the hardest part. Once faced with the specifics of our diseases, we can take action.

Researchers are reporting that a new vaccine designed to treat breast cancer appears to be safe in women with advanced disease. It showed signs of slowing down tumor growth too.

The Neuvenge vaccine, made by Dendreon Corporation -- maker of the Provenge prostate cancer vaccine -- targets the aggressive Her-2 positive form of breast cancer, which affects 20 to 30 percent of breast cancer patients. Using immune cells from a cancer patient's own body, Neuvenge is a tailor-made therapy.

Reports about Neuvenge, published in the Journal of Clinical Oncology, indicate the vaccine did not cause any serious side effects and of the 18 women who participated in the Phase I study, there was a reduction in the size of a tumor in one patient. In three other women, the disease seemed to stabilize for as long as a year.

At the 2007 meeting of the American Society of Clinical Oncology, results were presented from a clinical trial that stated -- Continuous maintenance therapy may improve survival among patients with metastatic colorectal cancer.

Maintenance therapy is used when a patient's cancer is stable and not exhibiting signs of progression. Researchers want to find a way to improve survival, but they also want to find a program that is not too intense and will have limited side effects.

This brings us to the study that was done on 202 patients with metastatic colorectal cancer. The patients were split in two groups, one group received continuous maintenance chemotherapy with a drug called Eloxatin (oxaliplatin). The second group was only treated again with chemotherapy once their cancer had started to progress.

Shorter courses of radiation therapy may be in order for women with early-stage breast cancer. And the largest study to test this suggests the abbreviated treatment time in no way affects risk of recurrence.

Often, the greatest hassle of radiation is getting to and from appointments, every weekday, for many weeks. With less frequent visits, life could get a whole lot easier.

Dr. John Dewar of the University of Dundee in Scotland led a two-part study of nearly 4,500 women in the United Kingdom to test courses of radiation and found five years later that cancer recurrences were low -- about two to five percent -- for women who received both longer and shorter durations of therapy. There were so few recurrences -- 158 -- that doctors believe the treatments are equivalent. They just can't say this with certainty yet.

This is great news for patients traveling great distances to their treatment facilities. Other benefits of shorter radiation timelines are less swelling and shrinkage of breast tissue and less enlargement of blood vessels.

Melanoma that has spread to other areas of the body is a very difficult cancer to treat successfully. It usually does not respond well to chemotherapy. Sadly, those diagnosed with metastatic melanoma survive only about a year after diagnosis.

The combination of Taxol (paclitaxel) with carboplatin, added to an agent that prevents the growth of blood vessels called bevacizumab has been shown to significantly delay the spread of tumors in patients with advanced melanoma. A Phase II clinical trial showed that tumor growth was delayed by almost six months; typically these cancers begin to start spreading again in about eight weeks.

Dr. Domingo Perez, M.D., the lead author of the study says "The clinical benefit may seem small, but in the world of melanoma where there is very little progress, this is certainly a strong indication that the combination of chemotherapy with an antiangiogenic agent may be a valid treatment strategy for these patients."

Arsenic trioxide sold under the brand name Trisenox, is approved for patients with a rare leukemia named acute promyelocytic leukemia (APL).

APL is a form of acute myeloid leukemia, about 1,500 people are diagnosed every year with this rare disease. Standard treatment involves chemotherapy and a form of vitamin A -- alltrans retinoic acid. This therapy helps about 70-80 percent of patient gain long term-remissions. About 25 percent of patients do relapse and are no longer responsive to treatment.These patients often are treated with arsenic trioxide.

A study was sponsored by The National Cancer Institute to see if the addition of arsenic trioxide along with the standard therapy for first line treatment would prove better survival rates.

I wrote on May 29 about my worry regarding a dry, flaky patch of skin on my nose. Unsure of the status of this unusual spot, I immediately called my dermatologist and made an appointment -- which did not end up being all that immediate. The earliest slot available for addressing my personal crisis was June 12 at 11 AM. I took it. And then the stars aligned and I got a call on this very same day.

"We have a cancellation tomorrow. Do you want to come in then?" said the voice on the other end of the phone. Yes, yes, yes, I wanted it. And so I took this slot instead.

Yesterday I met with my dermatologist. The good news is: what I found on the bridge of my nose is not cancer. The bad news is: it was trying really hard to become cancer.

Breast cancer drug Herceptin has been approved in Europe for use with hormonal therapy for postmenopausal patients with HER2 and hormone receptor positive metastatic disease.

Herceptin, made by Swiss drugmaker Roche Holding AG, is already approved in Europe for early and metastatic HER2-positive breast cancer.

This new approval is based on data from an international late stage clinical trial showing the combination of Herceptin with hormonal therapy doubled the median progression-free survival time.

Back in the news: the link between hormone replacement therapy (HRT) and breast cancer. This time, the connection is seemingly more conclusive than before, when some argued that many factors influence the risk of breast cancer, that HRT could not do the job all on its own.

Now, two separate studies offer up powerful evidence that HRT is linked to tumor growth. Case in point: when use of the therapy drops, so do incidences of breast cancer.

New figures in the New England Journal of Medicine suggest there have been 16,000 fewer cases of breast cancer nationwide since mid-2002, when women stopped taking their hormone pills following the federal Women's Health Initiative announcement connecting the therapy with increased risk of breast cancer, stroke, and heart attack.

Many did not want to believe HRT was to blame for so many breast cancer diagnoses. And maybe it's not the actual cause of the disease, but the fuel for tumors trying to grow.

These new findings do not appear to be a statistical fluke, says one doctor. Numbers have been computed and re-computed, and the message is clear: HRT is strongly implicated as the guilty party. There is just no other culprit, says a statistician at the National Cancer Institute.

Wyeth, maker of Premarin and Prempro -- two forms of hormone therapy -- continues to caution women against drawing any conclusions about HRT and breast cancer. There still may be broader explanation for the decline in cases, say their spokespeople.

A new study of mice implanted with human breast cancer cells shows the spread of the disease to the lungs -- a common metastasis site -- is caused by the abnormal activation of four specific genes working together.

The study, published in the journal Nature, indicates that shutting off the genes one by one can slow the growth and spread of this cancer. But turning off all four at one time almost completely stops the process. In mice anyway.

These genes are no strangers to researchers who have known for some time about their existence and functions. They just know more about them now.

The four genes work together at every step of the metastatic process to allow a breast tumor to develop blood vessels, let tumor cells enter the vessel walls and lungs, and permit them to pass out of the lung vessels and resume growth. New analysis shows that blocking these genes significantly reduces the tangle of blood vessels, making it harder for cancer cells to escape.

Researchers, who say the four genes are among 18 they associate with breast cancer metastasis, report that one implication of this study is clear: combined use of drug therapy may be more effective at inhibiting the activity of multiple gene targets.

The idea of music as a healing influence which could affect health and behavior is at least as old as the writings of Aristotle and Plato. The American Music Therapy Association (AMTA) promotes a vast amount of research exploring the benefits of music as therapy through publication of the Journal of Music Therapy, Music Therapy Perspectives and other sources. A substantial body of literature exists to support the effectiveness of music therapy.

You don't have to have a particular music ability to benefit from music therapy. No particular style of music is more therapeutic than any other. You just need to enjoy your experience. Music will lower stress and help you relax. It has been proven that it reduces acute and chronic pain. Even during child birth. It can elevate moods to counteract depression and it can counteract apprehension or fear.

So today just sit back and listen to some music, do some drumming or percussion rhythms, hum some tunes, blow on a flute or harmonica even if you don't know any particular songs. Be creative. Take advantage of the sunshine and beautiful weather and just step outside and listen to the birds, the wind, and the rhythm of mother nature. The stand by of anything else is to plug in a favorite CD and close your eyes and just let it sink in.

More and more media reports are mentioning the potential merits of marijuana. The most recent headlines say the active ingredient in the drug cuts tumor growth in common lung cancers in half and greatly reduces the ability of the cancer to spread.

Researchers at Harvard University tested marijuana's main ingredient, delta-tetrahydrocannabinol or THC, in both lab and mouse studies and say their experiments are the first to show THC inhibits the growth of cancer.

Researchers are not certain why THC inhibits tumor growth, but it could be that the substance activates molecules that arrest the cell cycle. THC may also interfere with angiogenesis and vascularization, which promotes cancer growth.

There is a long way to go in the study of THC. Yet "the beauty of this study is that we are showing that a substance of abuse, if used prudently, may offer a new road to therapy against lung cancer," says Anju Preet, Ph.D., a researcher in the Division of Experimental Medicine.

A new study shows certain genes may make some lung cancer patients more sensitive to chemotherapy. This is a good thing -- increased sensitivity in this case means lower doses of drug therapy work as good or better than higher doses.

Researchers looked at more than 21,000 genes in cells common to non-small-cell lung cancer, the most common type of the disease. Of these genes, 87 came up with heightened sensitivity to the chemotherapy drug Taxol. To be exact, the genes were 1,000 times more sensitive when exposed to the drug for 48 hours.

Chemotherapy is a very blunt instrument, says one researcher. Locating genes that make chemotherapy drugs more potent at lower doses is a critical step toward tailoring treatment and minimizing side effects for patients.

Two other drugs -- Navelbine and Gemzar -- were tested on six of the Taxol-sensitive genes. The genes did not respond to these drugs.

Hormonal therapy for prostate cancer can cause many side effects, one being bone loss. The goal of the hormonal therapy is to reduce the levels of the male hormones, called androgens, in the body. The main androgen is testosterone. Androgens can stimulate prostate cells to grow and lowering the levels often makes prostate cancer cells shrink or grow more slowly.

The Annals of Internal Medicine published an article that says Fosamax (alendronate) can prevent and even reverse bone loss associated with hormonal treatment for prostate cancer.

A trial was conducted that showed after one year bone density had increased among patients treated with Fosamax but had decreased among patients who received a placebo.

If you are receiving hormonal treatment for prostate cancer ask your doctor about a bisphosphonate, like Fosamax to control bone loss.